DOCSLIB.ORG

WO 2017/080945 Al 18 May 20 17 (18.05.2017) W P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2017/080945 Al 18 May 20 17 (18.05.2017) W P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/080945 Al 18 May 20 17 (18.05.2017) W P O P C T (51) International Patent Classification: (GB). HUNTER, Karl, John; Unilever R&D Colworth A61Q 15/00 (2006.01) A61K 8/27 (2006.01) Sharnbrook, Bedford, Bedfordshire MK44 1LQ (GB). A61K 8/73 (2006.01) A61K 8/23 (2006.01) (74) Agent: WARNER, Guy, Jonathan; Unilever PLC, Uni A61K 8/20 (2006.01) A61K 8/19 (2006.01) lever Patent Group, Colworth House, Sharnbrook, Bedford A61K 8/26 (2006.01) Bedfordshire MK44 1LQ (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP20 16/076807 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 7 November 2016 (07.1 1.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 15 193578.0 9 November 2015 (09. 11.2015) EP SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (71) Applicant (for AE, AG, AU, BB, BH, BN, BW, BZ, CA, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, CY, EG, GB, GD, GH, GM, IE, IL, IN, KE, KN, KW, LC, ZW. LK, LS, MT, MW, MY, NA, NG, NZ, OM, PG, QA, RW, SA, (84) Designated States (unless otherwise indicated, for every SC, SD, SG, SL, SZ, TT, TZ, UG, VC, ZA, ZM, Z W only): kind of regional protection available): ARIPO (BW, GH, UNILEVER PLC [GB/GB]; a company registered in Eng GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, land and Wales under company no. 41424 of Unilever TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, House, 100 Victoria Embankment, London Greater Lon TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, don EC4Y 0DY (GB). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant (for all designated States except AE, AG, AU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, BB, BH, BN, BW, BZ, CA, CY, EG, GB, GD, GH, GM, IE, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, IL, IN, KE, KN, KW, LC, LK, LS, LT, MT, MW, MY, NA, GW, KM, ML, MR, NE, SN, TD, TG). NG, NZ, OM, PG, QA, RW, SA, SC, SD, SG, SL, SZ, TT, Declarations under Rule 4.17 : TZ, UG, US, VC, ZA, ZM, ZW): UNILEVER N.V. [NL/NL]; Weena 455, 301 3 AL Rotterdam (NL). — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (71) Applicant (for US only): CONOPCO, INC., D/B/A UNI¬ — as to the applicant's entitlement to claim the priority of the LEVER [US/US]; 800 Sylvan Avenue AG West, S. Wing, earlier application (Rule 4.1 7(in)) Englewood Cliffs, NJ 07632 (US). — of inventorship (Rule 4.17(iv)) (72) Inventors: BERRY, Mark, John; Unilever R&D Col- worth Sharnbrook, Bedford, Bedfordshire MK44 1LQ Published: (GB). CHANDLER, Ian, Christopher; Unilever R&D — with international search report (Art. 21(3)) Colworth Sharnbrook, Bedford, Bedfordshire MK44 1LQ © o00 © (54) Title: ANTI-PERSPIRANT COMPOSITION (57) Abstract: An anti-perspirant composition comprising: (a) chitosan or a salt thereof, with a weight average molecular weight of greater than 80 kDa; and (b) an alumimum, zinc, magnesium or copper salt or mixture thereof wherein the composition comprises less than 3 wt% of alumimum salt. ANTI-PERSPIRANT COMPOSITION Field of the invention The invention relates to an anti-perspirant composition that contains low or no aluminium salt. Background of the invention Current anti-perspirant ingredients are based on aluminium, but inorganic salts have the effect of leaving white patches on clothes. Additionally there is a perceived health risk associated with aluminium. The current approach is to reduce the amount of aluminium in antiperspirants or to use additional metal salts such as those of zirconium. However, this approach tends to lower the efficacy of the formulation and hence prove more expensive. Zirconium-based antiperspirants tend to leave yellow patches on clothes. US 2009/0016978 A 1 (Courtois et al.) describes an antiperspirant composition comprising a carrier substance and a water-soluble or water-dispersible thiolated polymer. The prior art inventors believe that the thiol groups of the thiomer enable or enhance the polymer's ability to act as a mucoadhesive and that this ability enables or enhances the antiperspirant activity of the thiomer. "Mucoadhesives" are materials that can attach to mucin in a biological surface. The prior art inventors further believe that the antiperspirant activity results, at least in part, from the ability of the thiomers to act as pore blockers. The thiomers, when swollen by water, are thought to serve to as plugs that may, at least in part, block the exit of sweat from eccrine sweat glands. It is essential for the invention that the thiomer is water-soluble or water-dispersible in order for it to dissolve or disperse in eccrine sweat. WO 03/042251 (The Procter & Gamble Company) discloses compositions comprising chitosan in the form of a network of nano-sized fibres. Traditional chitosan is usually semi-crystalline and only soluble in acidic medium, typically in a pH range of from 1 to 5 limiting homogeneous formulation. A process for producing the network of nano- sized fibres is described involving the steps of forming an aqueous solution, neutralising the chitosan just to the point of precipitation, and homogenising the resulting suspension. It was observed that the minimum concentration of chitosan to inhibit Malassezia furfur (yeast implicated in dandruff) was lower than expected. This document also discloses an anti-dandruff composition comprising from about 0.01 % to about 5 % , preferably from about 0.5 % to about 2 % of chitosan by weight of the composition as the active anti-dandruff agent. The chitosan can be used in different applications, such as hair care, skin care, personal cleansing, odour control, wound care, blood management, oral care, film formation, controlled release of hydrophobic or hydrophilic materials, hard surface, fabric treatment, plant care, seed, grain, fruit and food protection, water purification and drug delivery. The chitosan compositions provide hair care benefits when formulated into products such as shampoos, conditioners, hairsprays, styling mousses and gels, hair tonics and hair colorants, especially anti-dandruff benefits and reduction of hair damage caused by the process of hair bleaching, permanent waving or coloration. Additionally, the compositions provide scalp benefits and conditioning properties such as softening, manageability and stylising of the hair. Specific examples are a shampoo, a conditioner, a dentifrice, a mouthwash, a non-abrasive gel, a chewing gum and a plant care composition. WO 2006/040092 (Beiersdorf AG) discloses an aerosol formulation comprising one or more anti-perspirants and/or deodorising substances and chitosan having a degree of deacetylation of 75 to 98 % , a viscosity of 5 to 10 mPas, a weight average molecular weight distribution of less than 300 000 Da and a number average molecular weight distribution of less than 100 000 Da. It appears that the disclosed chitosan preserves the skin flora rather than acting purely as a bacteriocide. In particular, the chitosan appears to bind to the bacteria preventing microbial decomposition of sweat leading to odour. Anti-perspirants reduce sweat formation with the aid of astringent compounds in them, which are predominantly aluminium salts, such as aluminium hydrochloride, activated aluminium chlorohydrate or aluminium zirconium. It is customary to combine astringents with antimicrobials in the same composition. Aerosol products generally contain active anti-perspirant substances in the form of solids, which are suspended in an oil phase. Conventional active deodorant substances include ethyl hexyl glycerol, methyl phenyl butanol and polyglyceryl-2-caprate. One aim of the invention described in WO 2006/040092 is to reduce whiteness on skin or clothes. The formulation comprises 0.001-2, preferably 0.01-1 , especially 0.015-0.3 % w/w chitosan. The formulation comprises 1-35, preferably 1-25, especially 1-20 % w/w anti-perspirant component. The formulation comprises preferably 0.01-10, especially 0.05-5 % w/w deodorant component. Examples disclosed are anhydrous compositions. WO 2006/040092 further discloses that the pressure container used for the aerosol can be made of a metal, protected glass, non-shatter glass or some other glass, or else of a plastic. The propellant gas is preferably chosen from a long list of suitable gases. US 2003/0133891 (Cognis Corporation) discloses a deodorising preparation containing nanoscale chitosans and/or chitosan derivatives with a particle diameter in the range from 10 to 300 nm. Chitosans have a bacteriostatic effect and a synergistic deodorising effect with esterase inhibitors and aluminium chlorohydrates. It is disclosed that absorption of nanoscale chitosans and/or chitosan derivatives by the Stratum Corneum is increased leading to long-lasting deodorising effect. The chitosan is normally used at levels of 0.01-5, preferably 0.1-1 , more particularly 0.2-0.6 % w/w.
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su
    Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones By Ming-Hsiu Yang Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chairperson Ryan A. Altman Michael D. Clift Apurba Dutta Michael F. Rafferty Jon A. Tunge Date Defended: April 26, 2017 The Dissertation Committee for Ming-Hsiu Yang certifies that this is the approved version of the following dissertation: Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones Chairperson Ryan A. Altman Date Approved: April 26, 2017 ii Abstract Ming-Hsiu Yang Department of Medicinal Chemistry, April 2017 The University of Kansas Fluorine plays an important role in drug design, because of some unique features imparted by fluorine. The incorporation of fluorine into small molecules can modulate molecular physicochemical properties, metabolic stability, lipophilicity, and binding affinity to the target proteins. However, few fluorinated molecules are biosynthesized by enzymes. This means incorporating fluorine into the molecules relies on synthetic methods. Thus, efficient synthetic strategies to access the molecules bearing a variety of privileged fluorinated moieties are important for drug discovery. Fluoroalkenes are an isopolar and isosteric mimic of an amide bond with distinct biophysical properties, including decreased H-bond donating and accepting abilities, increased lipophilicity, and metabolic stability. Moreover, fluoroalkenes can also serve as probes for conducting conformational analyses of amides. These potential applications require the development of efficient methods to access fluoroalkenes. In chapter 2, a Shapiro fluorination strategy to access peptidomimetic fluoroalkenes is demonstrated.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • Review of the Regulation of Products at the Interface Between Cosmetics and Therapeutic Goods
    PO Box 100, Woden ACT 2606, Australia Review of the regulation of products at the interface between cosmetics and therapeutic goods 18 March 2005 Review of the regulation of products at the interface between cosmetics and therapeutic goods March 2005 Prepared for the TGA by David B Newgreen Review of the regulation of products at the interface between cosmetics and therapeutic goods CONTENTS ABBREVIATIONS ..........................................................................................................ii ACKNOWLEDGMENTS .............................................................................................. iii TERMS OF REFERENCE ..............................................................................................iv SUMMARY.....................................................................................................................vi RECOMMENDATIONS..................................................................................................x 1. INTRODUCTION ......................................................................................................13 2. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN AUSTRALIA AND NEW ZEALAND ....................................................................23 2.1 AUSTRALIA......................................................................................................23 2.2 NEW ZEALAND ...............................................................................................33 3. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Opinion of the Scientific Committee on Consumer Safety on O
    SCCS/1613/19 Final Opinion Version S Scientific Committee on Consumer Safety SCCS OPINION ON the safety of aluminium in cosmetic products Submission II The SCCS adopted this document at its plenary meeting on 03-04 March 2020 SCCS/1613/19 Final Opinion Opinion on the safety of aluminium in cosmetic products – submission II ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final versions SCCS members Dr U. Bernauer Dr L. Bodin (Rapporteur) Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven SCCS external experts Dr A. Koutsodimou Dr A. Simonnard Prof. W. Uter All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 16 December 2019 until 17 February 2020). Comments received during this time period are considered by the SCCS. For this Opinion, some changes occurred, in particular in sections 1, 3.2, 3.3.4.5, 3.3.8.1, 3.5, as well as in related discussion parts and conclusion (question 1). The list of references has also been updated.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids. It is notable that breast cysts, as for Antiperspiran breast cancers, start most frequently in the upper outer quadrant of the breast, which is the region closest to the site of underarm antiperspirant application. Mechanistic Copyright: © 2019 Philippa D Darbre. evidence is reviewed for a link between aluminium levels in breast tissue, cyst Clinical Dermatology: Research And Therapy. This is an open access article formation and development of breast cancer. If excessive use of antiperspirant is a distributed under the Creative cause of breast cysts, then reduction or cessation of use could provide a preventative Commons Attribution License, which or even treatment strategy. Furthermore, if cyst formation from antiperspirant use is permits unrestricted use, distribution, an indicator of increased risk for breast cancer, then reduction in use of antiperspirant and reproduction in any medium, provided the original work is properly could also provide a strategy for reducing breast cancer risk.
    [Show full text]
  • Queensland Poisons Information Centre Annual Report 2019
    Queensland Poisons Information Centre Annual Report 2019 13 11 26 www.childrens.health.qld.gov.au/poisonsinformationcentre Poisons Information Centre Queensland Children’s Hospital Pharmacy Department, Level 2 501 Stanley Street South Brisbane Qld 4101 Table of Contents Mission Statement ............................................................................................................................................................ 4 Services and Operation ..................................................................................................................................................... 4 Location ......................................................................................................................................................................... 4 Telephone Access .......................................................................................................................................................... 4 Hours of Operation ........................................................................................................................................................ 4 Website .......................................................................................................................................................................... 4 Personnel ....................................................................................................................................................................... 5 External Consultants .....................................................................................................................................................
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]